The experimental siRNA agent led to prolonged Lp(a) reduction of more than 90%, extended data from the phase 1 trial show, supporting the move to phases 2 and 3 trials.
A drug targeting mRNA essential for APO C-III production provided a 50% reduction in triglycerides in BRIDGE-TIMI 73a, the largest ever observed in a controlled trial.
Robert J. Romanelli - Profile rand.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rand.org Daily Mail and Mail on Sunday newspapers.